These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 31683978)

  • 1. Monocytic Myeloid Derived Suppressor Cells in Hematological Malignancies.
    Palumbo GA; Parrinello NL; Giallongo C; D'Amico E; Zanghì A; Puglisi F; Conticello C; Chiarenza A; Tibullo D; Raimondo FD; Romano A
    Int J Mol Sci; 2019 Nov; 20(21):. PubMed ID: 31683978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of myeloid-derived suppressor cells in hematologic malignancies.
    Gunes EG; Rosen ST; Querfeld C
    Curr Opin Oncol; 2020 Sep; 32(5):518-526. PubMed ID: 32675593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decitabine shows potent anti-myeloma activity by depleting monocytic myeloid-derived suppressor cells in the myeloma microenvironment.
    Zhou J; Shen Q; Lin H; Hu L; Li G; Zhang X
    J Cancer Res Clin Oncol; 2019 Feb; 145(2):329-336. PubMed ID: 30426212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alteration of functionality and differentiation directed by changing gene expression patterns in myeloid-derived suppressor cells (MDSCs) in tumor microenvironment and bone marrow through early to terminal phase of tumor progression.
    Mahanti K; Saha J; Sarkar D; Pramanik A; Roy Chattopadhyay N; Bhattacharyya S
    J Leukoc Biol; 2024 Apr; 115(5):958-984. PubMed ID: 38236200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prognostic value and therapeutic targeting of myeloid-derived suppressor cells in hematological cancers.
    Fan R; De Beule N; Maes A; De Bruyne E; Menu E; Vanderkerken K; Maes K; Breckpot K; De Veirman K
    Front Immunol; 2022; 13():1016059. PubMed ID: 36304465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasticity of myeloid-derived suppressor cells in cancer.
    Tcyganov E; Mastio J; Chen E; Gabrilovich DI
    Curr Opin Immunol; 2018 Apr; 51():76-82. PubMed ID: 29547768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumour-activated liver stromal cells regulate myeloid-derived suppressor cells accumulation in the liver.
    Zhang H; He G; Kong Y; Chen Y; Wang B; Sun X; Jia B; Xie X; Wang X; Chen D; Wei L; Zhang M; Zeng H; Chen H
    Clin Exp Immunol; 2017 Apr; 188(1):96-108. PubMed ID: 28019655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunological dysregulation in multiple myeloma microenvironment.
    Romano A; Conticello C; Cavalli M; Vetro C; La Fauci A; Parrinello NL; Di Raimondo F
    Biomed Res Int; 2014; 2014():198539. PubMed ID: 25013764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myeloid-derived suppressor cells in hematological malignancies: friends or foes.
    Lv M; Wang K; Huang XJ
    J Hematol Oncol; 2019 Oct; 12(1):105. PubMed ID: 31640764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor conditions induce bone marrow expansion of granulocytic, but not monocytic, immunosuppressive leukocytes with increased CXCR2 expression in mice.
    Bian Z; Shi L; Venkataramani M; Abdelaal AM; Culpepper C; Kidder K; Liang H; Zen K; Liu Y
    Eur J Immunol; 2018 Mar; 48(3):532-542. PubMed ID: 29120053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myeloid-Derived Suppressor Cells: Immune-Suppressive Cells That Impair Antitumor Immunity and Are Sculpted by Their Environment.
    Ostrand-Rosenberg S; Fenselau C
    J Immunol; 2018 Jan; 200(2):422-431. PubMed ID: 29311384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myeloid Cell Modulation by Tumor-Derived Extracellular Vesicles.
    Arkhypov I; Lasser S; Petrova V; Weber R; Groth C; Utikal J; Altevogt P; Umansky V
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32878277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Emerging Role of Myeloid-Derived Suppressor Cells in the Glioma Immune Suppressive Microenvironment.
    Mi Y; Guo N; Luan J; Cheng J; Hu Z; Jiang P; Jin W; Gao X
    Front Immunol; 2020; 11():737. PubMed ID: 32391020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conditioned media from the renal cell carcinoma cell line 786.O drives human blood monocytes to a monocytic myeloid-derived suppressor cell phenotype.
    Okada SL; Simmons RM; Franke-Welch S; Nguyen TH; Korman AJ; Dillon SR; Gilbertson DG
    Cell Immunol; 2018 Jan; 323():49-58. PubMed ID: 29103587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pro-Tumoral Inflammatory Myeloid Cells as Emerging Therapeutic Targets.
    Szebeni GJ; Vizler C; Nagy LI; Kitajka K; Puskas LG
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27886105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TIME Is a Great Healer-Targeting Myeloid Cells in the Tumor Immune Microenvironment to Improve Triple-Negative Breast Cancer Outcomes.
    Singh S; Zhang XHF; Rosen JM
    Cells; 2020 Dec; 10(1):. PubMed ID: 33374595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutualistic Effects of the Myeloid-Derived Suppressor Cells and Cancer Stem Cells in the Tumor Microenvironment.
    Tanriover G; Aytac G
    Crit Rev Oncog; 2019; 24(1):61-67. PubMed ID: 31679221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Development and Homing of Myeloid-Derived Suppressor Cells: From a Two-Stage Model to a Multistep Narrative.
    Karin N
    Front Immunol; 2020; 11():557586. PubMed ID: 33193327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bio-HMGB1 from breast cancer contributes to M-MDSC differentiation from bone marrow progenitor cells and facilitates conversion of monocytes into MDSC-like cells.
    Su Z; Ni P; She P; Liu Y; Richard SA; Xu W; Zhu H; Wang J
    Cancer Immunol Immunother; 2017 Mar; 66(3):391-401. PubMed ID: 27987020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The CCAAT/Enhancer-Binding Protein Family: Its Roles in MDSC Expansion and Function.
    Wang W; Xia X; Mao L; Wang S
    Front Immunol; 2019; 10():1804. PubMed ID: 31417568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.